Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data.
Saved in:
| Title: | Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. |
|---|---|
| Authors: | Scheid JF; Merck & Co., Inc., Rahway, NJ, United States., Cunningham-Bussel K; Merck & Co., Inc., Rahway, NJ, United States., Kim N; Merck & Co., Inc., Rahway, NJ, United States., Agarwal S; Merck & Co., Inc., Rahway, NJ, United States., Nieddu G; Merck & Co., Inc., Rahway, NJ, United States., Cote J; Merck & Co., Inc., Rahway, NJ, United States., Lemoine L; Merck & Co., Inc., Rahway, NJ, United States., Decaesteker T; Merck & Co., Inc., Rahway, NJ, United States., Mendez L; Merck & Co., Inc., Rahway, NJ, United States., Paul E; Merck & Co., Inc., Rahway, NJ, United States., Love-Gregory L; Merck & Co., Inc., Rahway, NJ, United States., Contreras AV; Merck & Co., Inc., Rahway, NJ, United States., Zhao X; Merck & Co., Inc., Rahway, NJ, United States., Franco-Dilone L; Merck & Co., Inc., Rahway, NJ, United States., Pang L; Merck & Co., Inc., Rahway, NJ, United States., Baltus GA; Merck & Co., Inc., Rahway, NJ, United States., Beaumont M; Merck & Co., Inc., Rahway, NJ, United States., Shah K; Merck & Co., Inc., Rahway, NJ, United States., Higginson-Scott N; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Kis-Toth K; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Otipoby KL; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Viney JL; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Sicard E; Altasciences, Montreal, QC, Canada., Rottey S; Universiteit Gent, Gent, Belgium., Sundy JS; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States., Van Dyck K; Merck & Co., Inc., Rahway, NJ, United States., Laethem T; Merck & Co., Inc., Rahway, NJ, United States., Larson P; Merck & Co., Inc., Rahway, NJ, United States., Sutradhar S; Merck & Co., Inc., Rahway, NJ, United States., Wnek R; Merck & Co., Inc., Rahway, NJ, United States., Bueters T; Merck & Co., Inc., Rahway, NJ, United States., Lai E; Merck & Co., Inc., Rahway, NJ, United States., Stoch SA; Merck & Co., Inc., Rahway, NJ, United States., Iwamoto M; Merck & Co., Inc., Rahway, NJ, United States., Robbins JA; Merck & Co., Inc., Rahway, NJ, United States. |
| Source: | ImmunoHorizons [Immunohorizons] 2025 Mar 26; Vol. 9 (5). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101708159 Publication Model: Print Cited Medium: Internet ISSN: 2573-7732 (Electronic) Linking ISSN: 25737732 NLM ISO Abbreviation: Immunohorizons Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40139976 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Scheid+JF%22">Scheid JF</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Cunningham-Bussel+K%22">Cunningham-Bussel K</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Kim+N%22">Kim N</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Agarwal+S%22">Agarwal S</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Nieddu+G%22">Nieddu G</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Cote+J%22">Cote J</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Lemoine+L%22">Lemoine L</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Decaesteker+T%22">Decaesteker T</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Mendez+L%22">Mendez L</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Paul+E%22">Paul E</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Love-Gregory+L%22">Love-Gregory L</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Contreras+AV%22">Contreras AV</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Zhao+X%22">Zhao X</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Franco-Dilone+L%22">Franco-Dilone L</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Pang+L%22">Pang L</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Baltus+GA%22">Baltus GA</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Beaumont+M%22">Beaumont M</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Shah+K%22">Shah K</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Higginson-Scott+N%22">Higginson-Scott N</searchLink>; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Kis-Toth+K%22">Kis-Toth K</searchLink>; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Otipoby+KL%22">Otipoby KL</searchLink>; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Viney+JL%22">Viney JL</searchLink>; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Sicard+E%22">Sicard E</searchLink>; Altasciences, Montreal, QC, Canada.<br /><searchLink fieldCode="AU" term="%22Rottey+S%22">Rottey S</searchLink>; Universiteit Gent, Gent, Belgium.<br /><searchLink fieldCode="AU" term="%22Sundy+JS%22">Sundy JS</searchLink>; Pandion Therapeutics, Inc., a subsidiary of Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Van+Dyck+K%22">Van Dyck K</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Laethem+T%22">Laethem T</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Larson+P%22">Larson P</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Sutradhar+S%22">Sutradhar S</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Wnek+R%22">Wnek R</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Bueters+T%22">Bueters T</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Lai+E%22">Lai E</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Stoch+SA%22">Stoch SA</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Iwamoto+M%22">Iwamoto M</searchLink>; Merck & Co., Inc., Rahway, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Robbins+JA%22">Robbins JA</searchLink>; Merck & Co., Inc., Rahway, NJ, United States. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101708159%22">ImmunoHorizons</searchLink> [Immunohorizons] 2025 Mar 26; Vol. 9 (5). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101708159 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2573-7732 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2225737732%22">25737732 </searchLink><i>NLM ISO Abbreviation: </i>Immunohorizons <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40139976 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1093/immhor/vlaf005 Languages: – Code: eng Text: English Titles: – TitleFull: Safety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascending dose trial data. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Scheid JF – PersonEntity: Name: NameFull: Cunningham-Bussel K – PersonEntity: Name: NameFull: Kim N – PersonEntity: Name: NameFull: Agarwal S – PersonEntity: Name: NameFull: Nieddu G – PersonEntity: Name: NameFull: Cote J – PersonEntity: Name: NameFull: Lemoine L – PersonEntity: Name: NameFull: Decaesteker T – PersonEntity: Name: NameFull: Mendez L – PersonEntity: Name: NameFull: Paul E – PersonEntity: Name: NameFull: Love-Gregory L – PersonEntity: Name: NameFull: Contreras AV – PersonEntity: Name: NameFull: Zhao X – PersonEntity: Name: NameFull: Franco-Dilone L – PersonEntity: Name: NameFull: Pang L – PersonEntity: Name: NameFull: Baltus GA – PersonEntity: Name: NameFull: Beaumont M – PersonEntity: Name: NameFull: Shah K – PersonEntity: Name: NameFull: Higginson-Scott N – PersonEntity: Name: NameFull: Kis-Toth K – PersonEntity: Name: NameFull: Otipoby KL – PersonEntity: Name: NameFull: Viney JL – PersonEntity: Name: NameFull: Sicard E – PersonEntity: Name: NameFull: Rottey S – PersonEntity: Name: NameFull: Sundy JS – PersonEntity: Name: NameFull: Van Dyck K – PersonEntity: Name: NameFull: Laethem T – PersonEntity: Name: NameFull: Larson P – PersonEntity: Name: NameFull: Sutradhar S – PersonEntity: Name: NameFull: Wnek R – PersonEntity: Name: NameFull: Bueters T – PersonEntity: Name: NameFull: Lai E – PersonEntity: Name: NameFull: Stoch SA – PersonEntity: Name: NameFull: Iwamoto M – PersonEntity: Name: NameFull: Robbins JA IsPartOfRelationships: – BibEntity: Dates: – D: 26 M: 03 Text: 2025 Mar 26 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 2573-7732 Numbering: – Type: volume Value: 9 – Type: issue Value: 5 Titles: – TitleFull: ImmunoHorizons Type: main |
| ResultId | 1 |
